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Abstract
Apolipoprotein A-IV amyloidosis is an uncommon form of the disease normally resulting in renal and cardiac
dysfunction. ApoA-IV amyloidosis was identified in 16 patients attending the National Amyloidosis Centre and
in eight clinical samples received for histology review. Unexpectedly, proteomics identified the presence of
ApoA-IV signal sequence residues (p.18-43 to p.20-43) in 16/24 trypsin-digested amyloid deposits but in
only 1/266 non-ApoA-IV amyloid samples examined. These additional signal residues were also detected in
the cardiac sample from the Swedish patient in which ApoA-IV amyloid was first described, and in plasma
from a single cardiac ApoA-IV amyloidosis patient. The most common signal-containing peptide observed in
ApoA-IV amyloid, p.20-43, and to a far lesser extent the N-terminal peptide, p.21-43, were fibrillogenic
in vitro at physiological pH, generating Congo red-positive fibrils. The addition of a single signal-derived
alanine residue to the N-terminus has resulted in markedly increased fibrillogenesis. If this effect translates
to the mature circulating protein in vivo, then the presence of signal may result in preferential deposition
as amyloid, perhaps acting as seed for the main circulating native form of the protein; it may also influence
other ApoA-IV-associated pathologies.
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of
Great Britain and Ireland.
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Introduction
Amyloidosis occurs when a diverse range of normal cir-
culating proteins misfold and subsequently deposit as
insoluble fibrillary masses in a range of tissues, resulting
in organ dysfunction and clinical disease [1]. There are
over 30 known amyloidogenic proteins associated with
human disease [2]. Amyloid deposits can be restricted
to specific organs – for example, fibrinogen Aα amyloid
is invariably found in the kidney [3]; with other amyloi-
dogenic proteins, such as transthyretin (TTR) or immu-
noglobulin light chains, amyloid can be detected in
multiple organs [4–7]. In some cases, the development
of the disease is associated with increased circulating
concentrations of the precursor proteins, common
examples being the kappa and lambda light chains aris-
ing from a monoclonal gammopathy [8] and serum
amyloid A, which is associated with a raised inflamma-
tory response [9]. With other proteins, including lyso-
zyme, TTR, and fibrinogen Aα, the presence of a
variant can result in protein destabilisation and the sub-
sequent formation of amyloid [10–12]. Amyloid
deposits can also arise from normal circulating levels
of wild-type proteins. This is notable in the case of
TTR, where amyloid deposits of wild-type protein are
commonly found in the hearts of the elderly [13,14],
possibly as a result of age-related oxidative changes [15].
Apolipoprotein A-IV (ApoA-IV) was originally identi-
fied as a new amyloid fibril protein in fibrils extracted
from cardiac tissue of a patient with senile systemic
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amyloidosis [now termed ATTR wild-type (ATTRwt)
amyloidosis] [16]. Additional biochemical studies
showed that the amyloidogenicity of ApoA-IV resided
in the N-terminus. It was later shown by the same group
that ApoA-IV and TTR were not co-deposited but occu-
pied anatomically distinct regions, demonstrating that
two types of amyloid can be present, and separately
deposited, in the same tissue [17]. There were few fur-
ther reports of ApoA-IV amyloid (AApoA-IV) since
typing relied mainly on immunological techniques and
few pathology laboratories had access to the original
high-quality antibody for typing.
The observation that a mass spectrometric-based pro-
teomics approach could be applied to identify proteins in
formalin-fixed, paraffin-embedded (FFPE) material
[18–21] led to the development of proteomics as a clini-
cal service for typing amyloid by Ahmet Dogan and col-
leagues at the Mayo Clinic [22–25]. Proteomics makes it
relatively easy to identify (and potentially quantify) any
of the currently known amyloidogenic proteins in clini-
cal samples. It was then determined by the Mayo team
that ApoA-IV was a common constituent of amyloid
deposits and could be used as a signature protein,
together with serum amyloid P component and
apolipoprotein E, to identify the presence of amyloid
[24]. Whilst this was beneficial in typing amyloid by
proteomics, it caused some difficulty in the identification
of ApoA-IV as an amyloid protein rather than an
amyloid-associated signature protein. Proteomics was
used successfully at the Mayo Clinic to identify cases
of renal and cardiac ApoA-IV amyloidosis [26–29]. This
was based primarily on an unusual clinical presentation
coupled with a high number of ApoA-IV peptides iden-
tified by proteomics (spectral count) and the absence of
other obvious amyloidogenic proteins. These became
their new criteria for identifying ApoA-IV amyloid.
In our centre, we have developed further criteria for
the identification of ApoA-IV amyloid based on
clinical presentation together with morphological,
immunohistochemical, and proteomics behaviour.
We have also identified peptides containing signal
sequence (p.18-43, p.19-43, and p.20-43) in a number
of clinical ApoA-IV amyloid samples, suggesting that
this may influence amyloid deposition and also be of




Samples were collected and analysed as part of routine
clinical examination. Informed consent was obtained
from all patients and clinical care was in accordance
with the Declaration of Helsinki. The material collec-
tion and use for the original Swedish sample (#25)
were performed under a valid permit by the Ethics
Committee at Uppsala University Hospital (Ups
01-083).
Patients and samples
Fifteen patients with renal or cardiac dysfunction attend-
ing the UK NHS National Amyloidosis Centre (NAC)
clinics between March 2016 and October 2020 were
diagnosed with ApoA-IV amyloidosis (Table 1). Duode-
nal ApoA-IV amyloidosis was also diagnosed in a single
patient. Samples of FFPE tissue or fat aspirates were
obtained as part of routine diagnostic procedures and
were evaluated as previously reported using Congo red
staining, immunohistochemistry (IHC) with a panel of
antibodies, and proteomics analysis [30–32]. Serum was
prepared from blood taken from two healthy volunteers
and from three patients given an AApoA-IV diagnosis.
Eight tissue samples sent for histology review were also
diagnosed with ApoA-IV amyloid based on IHC and the
proteomics criteria. The FFPE block from the original
patient diagnosed with ApoA-IV amyloidosis [16] was
obtained from the Department of Immunology, Genetics
and Pathology, Uppsala, Sweden and was recut to obtain
6-μm sections which were stained with Congo red, fol-
lowed by IHC using an anti-TTR antibody [33] and an
anti-ApoA-IV antipeptide antibody [17]. Two separate
areas of TTR-positive and ApoA-IV-positive amyloid
were micro-dissected and captured.
Proteomics analysis
Full experimental details of our proteomics approach,
based on that of the Mayo Clinic, have been reported
previously [34]. Samples were originally analysed on a
Thermo Velos Orbitrap mass spectrometer coupled to
a Waters nanoACQUITY UPLC system and, more
recently, on a Thermo Q-Exactive Plus mass spectrome-
ter (Thermo Fisher Scientific, Bremen, Germany)
coupled to a Dionex Ultimate 3000 UPLC system
(Thermo Fisher Scientific). Data were analysed by Mas-
cot software (Matrix Science, London, UK) using the
Swiss-Prot human database. Search parameters were
charge states +2, +3, and +4; precursor mass tolerance
of 10 ppm; and 0.6 Da for HCD fragments; the more
intense 13C ion was normally selected for dissociation.
Trypsin was used as the in silico proteolytic enzyme,
with semi-trypsin included to identify additional non-
tryptic signal sequences. The significance level was set
at p < 0.05. Methionine oxidation was included as vari-
able modification. Separate MS analyses were per-
formed on the Q-Exactive Plus instrument using
parallel reaction monitoring (PRM) selecting for specific
12C ions of ApoA-IV peptides p.18-43, p.19-43, and
p.20-43 (MH3
3+ m/z 944.121, 892.087, and 868.408,
respectively). Data have been recorded in a separate pro-
teomics database; in January 2021, this database con-
tained 2100 clinical entries excluding controls,
external research samples, and fats following decellular-
isation treatment [35].
ApoA-IV immunoprecipitation
ApoA-IV proteinwas immunoprecipitated from serum col-
lected from three ApoA-IV patients (#1, #3, and #11) and
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from two healthy controls. A mouse monoclonal anti-
human ApoA-IV antibody (Santa Cruz Biotechnology,
Dallas, TX, USA) was buffer-exchanged into PBS using
BioSpin columns (Bio-Rad Laboratories, Watford, UK)
and incubated overnight with rotation at 4 C with
CNBR-activated Sepharose 4B beads (Sigma-Aldrich, St
Louis,MO,USA). The antibody beadswere used to immu-
noprecipitate ApoA-IV using the procedure described
previously for TTR [34].
Fibrillogenesis of ApoA-IV peptides p.18-43,
p.19-43, p.20-43, and p.21-43
Synthetic ApoA-IV peptides p.18-43, p.19-43, and
p.20-43, and the N-terminal peptide p.21-43 (peptide
purity > 95%) were purchased from Life Technologies
Limited, Paisley, UK. They were dissolved at 200 μg/ml
in phosphate-buffered saline (pH 7.4) containing 10 μM
thioflavin T (ThT) and placed in Costar 96-well plates
(Fisher Scientific, Loughborough, UK) in a BMG LAB-
TECH, FLUOstar Omega double-orbital shaker (BMG
LABTECH, Ortenberg, Germany). Three replicates for
each peptide were incubated at 37 C with shaking at
900 rpm, and ThT fluorescence (excitation at 440 nm,
emission at 480 nm) was recorded for 24 h at 500 s
intervals.
Transmission electron microscopy (TEM)
A drop of a suspension of fibrils, collected following 24 h
incubation, was loaded onto a formvar/carbon-coated
300-mesh copper grid and excess solvent was allowed to
dry at room temperature for 3min before blottingwithfilter
paper.Afterwashingwithwater for10s, thedrysamplewas
stainedwith2%uranyl acetate solution for1minandexam-
ined in a JEOL JEM-1400 Flash transmission electron
microscope (JEOL, Tokyo, Japan) operating at 120 kV.
Results
Cardiac ApoA-IV amyloidosis was initially diagnosed
in nine patients (all male, median age 77 years), renal
amyloidosis in six patients (five male and one female,
median age 68 years), and duodenal ApoA-IV amyloid-
osis in a single patient, all attending clinics at the
National Amyloidosis Centre (Table 1). All renal
patients had previous chronic kidney disease, with amy-
loid deposition but with no plasma cell dyscrasia or
clone noted. On 123I SAP scintigraphy, no visceral amy-
loid deposits were detected. All patients went on to
develop cardiac amyloid, from between 6 months and
7 years post-renal amyloid diagnosis. Cardiac amyloid





p.18-43 p.19-43 p.20-43 p.21-43 Notes
18ARAEVSADQVATVMWDYFSQLSNNA43K
1 Cardiac 8120 167/29 Y Y Y Y
2 Cardiac 6414 130/22 Y Y Y Y
3 Cardiac 4517 121/23 – Y Y Y Serum +ve for signal
4 Cardiac 3287 103/34 – Y Y Y
5 Cardiac 2686 78/16 – – – Y
6 Cardiac 2075 73/10 – – – Y
7 Cardiac 1591 47/10 – – – Y
8 Cardiac 1230 43/26 – Y Y Y
9 Cardiac 333 12/10 – – – –
10 Renal 8127 272/25 Y Y Y Y
11 Renal 4162 130/17 – – Y Y
12 Renal 3817 116/21 – Y Y Y
13 Renal 2079 60/14 – – Y Y
14 Renal 1789 42/21 – – – Y
15 Renal 825 32/11 – – Y Y
16 Duodenal 2361 87/22 – – – Y
17 Cardiac 10,176 332/33 – Y Y Y
18 Cardiac 7866 266/34 Y Y Y Y
19 Cardiac 7863 237/33 Y Y Y Y p.15-43 unconfirmed
20 Cardiac 2884 107/20 – Y Y Y ApoA-IV + TTR present
21 Renal 6226 136/13 – Y Y Y
22 Renal 6357 167/26 Y Y Y Y p.17-43 unconfirmed
23 Renal 883 16/7 – – – –
24 ENT 5996 188/31 – Y Y Y
25 Cardiac 4245 113/27 Y Y Y Y ApoA-IV + TTR present
Mascot score, significant mass spectra (spectral matches/unique significant peptides, USP). Further clinical details are shown in supplementary material, Table S1.
Patients 1–15 attended the NAC clinic and were diagnosed with cardiac or renal ApoA-IV amyloidosis. Patient 16 attended the clinic with localised amyloid in the
gut. FFPE blocks from patients 17–24 were received from other centres for histology review. The mature protein N-terminal peptide, p.21-43 (EVSADQVATVMW-
DYFSQLSNNAK) was present in 22/24 samples. Signal peptides were identified in 17/24 patient samples, with p.20-43 being the most common. Peptides p.15-43 and
p.17-43 were not confirmed by co-elution with standards. The block from the original ApoA-IV patient (#25) from Sweden was retrieved and re-analysed; ApoA-IV signal
peptides were present. Both TTR and ApoA-IV were identified in separate regions of the tissue from patients 20 and 25. ApoA-IV signal sequence was also present in a fat
biopsy and a blood sample collected from patient 3.
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deposition was assessed using a Tc-DPD scan on all
patients, all resulting in Perugini grade 0. A clinical sum-
mary is shown in supplementary material, Table S1. The
morphology in the renal and cardiac cases was different
but characteristic, in that amyloid presents as swathes of
medullary sheets in renal biopsies and can be minimal in
the cardiac tissue, with scanty deposits surrounding
myocytes or in vessels. IHC indicated the presence of
ApoA-IV in four cases, and also in a separate, non-
cardiac biopsy from patient 8. Other samples were not
tested with the ApoA-IV antibody. There was no evi-
dence for ApoA-IV immunostaining in any non-ApoA-
IV amyloid despite high ApoA-IV Mascot scores. In
each case, ApoA-IV was identified by proteomics as
the top scoring protein together with a low probability
for the presence of other candidate amyloid proteins.
The Mascot scores, which use a probability-based algo-
rithm, were high: in only one sample was the score less
than 800, which is ten times the minimum score of
80 used in our algorithm to confidently identify proteins.
This is in agreement with the criteria originally reported
by Dasari et al [26]. We re-examined the data in our clin-
ical proteomics database for the presence of ApoA-IV
amyloid using these criteria. ApoA-IV amyloid was
identified in eight histology review samples from cardiac
(4), renal (3), and oral mucosal (1) biopsies (#17–24).
Distinct areas of TTR and ApoA-IV were observed by
both IHC and proteomics in #20. In each of these addi-
tional cases, ApoA-IVwas the top scoring (highest prob-
ability) amyloid protein, with 7/8 scoring greater than
2400, which is 30-fold higher than the minimum accept-
able score. With the exception of fibrinogen Aα and
ApoA-I, which can be excluded by other criteria [32],
there were no other amyloid candidates present. Clinical
and morphological data, where available, were consis-
tent with the diagnosis. These data are summarised in
Table 1 and Figure 1 and are also expressed as a Scaffold
output (Proteome Software, Inc, Portland, OR, USA) in
supplementary material, Figure S1. ApoA-IV was pre-
sent with a minimum Mascot score of 80 in 55%
(1142/2075) of the samples in our database where
ApoA-IV was not identified as the amyloid type (supple-
mentary material, Table S2). This is not unexpected as it
is one of the three currently acknowledged amyloid sig-
nature proteins. It was the top scoring amyloid protein in
only 311 samples, with high scores (>2400) observed
in only eight (1.8%) of the samples (supplementary
material, Table S2 and Figure 1). Of the uncertain diag-
noses with a top ApoA-IV score, only 16 showed no evi-
dence for other amyloid proteins; the ApoA-IV scores
were relatively low (82–383) and there was no other rea-
son to consider ApoA-IV as the amyloid protein.
During the analyses of the clinical and histology review
ApoA-IV cases, we observed that the tryptic peptide
p.20-43 (AEVSADQVATVMWDYFSQLSNNAK) was
Figure 1. The ApoA-IV Mascot score histogram for all samples (light
blue bars); the histogram for ApoA-IV clinical amyloid samples is
shown as dark blue bars. The scores of the 24 clinical ApoA-IV
patients are also shown as open blue circles together with that of
the original Swedish sample (open diamond); in each of these cases,
ApoA-IV was the top scoring amyloid protein. Signal sequence was
detected in 17/24 samples (closed blue circles) and also in the
Swedish sample (closed red circle in diamond).
Figure 2. Normalised ion chromatograms (MH3
3+) for the signal-
containing peptides p.18-43, p.19-43, and p.20-43, together with
the N-terminal peptide p.21-43 for (A) authentic standards and
(B) patient 11. (C, D) MSMS spectra (MH3
3+) for the p.18-43 stan-
dard and patient 11. The common y ion series (y3–y15) is
highlighted.
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detected in 17/24 cases. This was unexpected as it corre-
sponds to a tryptic cleavage after p.20R in the signal region.
The rawdatawere reanalysedbyMascot using semi-trypsin
as the in silico protease: additional signal-containing pep-
tides were observed corresponding to p.18-43 (ARA-
EVSA…, n = 6) and p.19-43 (RAEVSA… n = 12),
together with single examples of p.17-43
(GARAEVSA…) and p.15-43 (VAGARAEVSA…).
Signal-containing peptides were present in a post-
mortem sample from a presumed cardiac TTR patient
(#20) where distinct areas of both ApoA-IV and TTR
immunostaining were observed (Table 1). The
N-terminal peptide p.21-43 (EVSA…) was present in
22/24 samples. There were also some examples of trun-
cated N-terminal peptides p.22-43 (VSA…) and p.23-
43 (SA…), but none without the expected p.43 lysine
C-terminus which is generated by trypsin in the sample
workup.This indicated thatApoA-IVamyloidwas asso-
ciatedwith the presence of signal sequence.A single sig-
nal peptide, p.19-43, was also identified in a fat sample,
from patient 3, which had been treated by the decellular-
isation method designed to remove non-amyloid
deposits and enhance proteomic identification [35]. As
controls, all other non-ApoA-IV samples with an
ApoA-IV score greater than 800 were examined
(n = 266); theN-terminal peptide (p.21-43)was present
in 27% of samples; however, only a single sample of fat
showed evidence of p.18-43, and this was identified
from a single MSMS spectrum. The protein coverage
of ApoA-IV for the ApoA-IV patients and controls with
high ApoA-IV signature scores is shown in supplemen-
tary material, Figure S2. This indicates that ApoA-IV
amyloid is also associated with a reduced C-
terminal load.
The FFPE block of cardiac tissue from the original
Swedish patient (#25) diagnosed with ApoA-IV amyloid-
osis was obtained, and sections were recut and analysed
by histochemistry: distinct areas were observed exhibiting
ApoA-IV and TTR immunoreactivity, respectively, in
agreement with the original data. Two areas of each
immuno-positive region were laser-dissected and prepared
for proteomics using our standard procedure. In the ApoA-
IV-positive section, proteomics identified ApoA-IV as the
top scoring protein (Mascot scores 4245 and 2547),
together with the signature proteins SAP and ApoE. Other
lower scoring (score < 750) proteins were also observed
including TTR, ApoA-I, and kappa light chain. Three
signal-containing ApoA-IV peptides, p.18-43, p.19-43,
and p.20-43, were present together with theN-terminal pep-
tide p.21-43. In the TTR immuno-positive area, TTR was
Figure 3. (A) Fibrillogenesis at pH 7 and 37 C of the signal-containing peptides p.18-43, p.19-43, and p.20-43, and the N-terminal peptide
p.21-43 analysed at the same time. (B) Three separate experiments were performed for each peptide, and the mean (SD) of the change in ThT
fluorescence emission between 0.25 and 18 h is shown. Fluorescence intensity is shown in arbitrary units (a.u.). Panels C1–C4 show the bright
field Congo red staining for the p.20-43 fibrils together with the fluorescence with and without the polarising filter, and the electron micro-
graph of the p.20-43 fibrils (after 24 h of incubation).
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the top scoring protein (2753 and 2000); ApoA-IVwas pre-
sent with lower scores (<600) and therewas no evidence for
signal peptides, which is consistent with ApoA-IV in this
region being a co-deposited signature protein.
To confirm the identity of these Mascot-identified signal-
containing peptides, four authentic peptide samples (p.18-,
p.19-, p.20-, and p.21-43) were analysed under our standard
LCMS conditions. Peptides p.15-43 and p.17-43 were not
compared against standards and their identity is based on
Mascot search analysis only. Peptides p.18-43 and p.19-43
essentially co-eluted at 26.8 min, with p.20-43 and the N-
terminal peptide p.21-43 eluting later at 28.8 and 29.1 min,
respectively. Each peptide generated a similar set of y ions
(y3–y15) together with characteristic b ions. The clinical
ApoA-IV samples and the Swedish cardiac sample showed
the same relative retention times and elution pattern as the
standards (Figure 2), and generated similar MSMS spectra
(supplementary material, Figure S3). These data confirm that
there is a signal-containing protein in ApoA-IV amyloid.
Since any ApoA-IV deposited in amyloid must have
come from the circulation, serum from patients 1, 3, and
11, whose samples showed high ApoA-IV scores, was
immunoprecipitated with anti-ApoA-IV antiserum and the
sample was subjected to PRM mass spectrometric analysis
targeting the signal peptides p.18-43, p.19-43, and
p.20-43. All three peptides were present only in the immu-
noprecipitate from patient 3 (supplementary material,
Figure S4), although none were identified in the remaining
two ApoA-IV patients, or in serum from two healthy con-
trols. These data are consistent with a very low normal cir-
culating concentration of signal-containing proteins.
To determine whether these additional signal residues
could influence the deposition of amyloid, the authentic
peptides were incubated in PBS buffer at 37 Cwith gentle
shaking, and fibril formation was measured by ThT fluo-
rescence emission as previously described [36]. Although
neither of the arginine-containing signal peptides
(p.18-43 and p.19-43) showed any fibril formation, the
most common signal-containing peptide, p.20-43, and to
a much lesser extent the N-terminal peptide p.21-43 were
fibrillogenic under these mild conditions (Figure 3). The
fibrils from the p.20-43 peptide exhibited the classic amy-
loid green birefringence following Congo red staining,
and the electronmicrographs were consistent with amyloid
fibrils. Small specks of positive material could also be
observed for the p.21-43 (N-terminal peptide) preparation;
however, there was no evidence for amyloid fibrils in the
incubates of p.18-43 and p.19-43. The addition of a single
alanine to the normal N-terminal peptide, p.21-43, has
markedly increased its fibrillogenicity; this effect is lost
by further extension with arginine (p.18-43 and p.19-43).
Discussion
Mature ApoA-IV is a 376-residue (p.21-396) circulating
protein that is involved in a number of physiological pro-
cesses. ApoA-IV amyloid deposits were first recognised
in a Swedish cardiac patient through traditional protein
biochemistry analyses and the development of specific
and complementary immunohistochemical methods
[16]. The advent of diagnostic amyloid proteomics pio-
neered at the Mayo Clinic revolutionised the field and
made it possible to rapidly type amyloid [37,38].
ApoA-IV is a common constituent of amyloid tissue;
therefore its identification alone is insufficient to identify
the amyloid protein: here, the proteomics criteria identi-
fied by the Mayo Clinic, using an abnormally high num-
ber of ApoA-IV spectra coupled with the absence of
other amyloid proteins, are central to confirming
ApoA-IV amyloid. In our centre, we use theMascot pro-
tein database search engine, which generates a
probability-based score dependent on the quality and
number of individual mass spectra to identify proteins
(http://matrixscience.com). Although it is not a quantita-
tive measure, the score is a surrogate for protein amount
and is helpful in distinguishing the amyloid protein from
contaminants. Our algorithm identifies ApoA-IV where
it is the top scoring protein, normally with scores in
excess of 1000, in the absence of other candidate amy-
loid proteins. Whilst our data are in general agreement
with those of the Mayo Clinic, we note that a low score
(or low total spectral count) does not preclude the pres-
ence of ApoA-IV amyloid. Equally, the absence of other
amyloid proteins may be insufficient to distinguish
ApoA-IV amyloid from the amyloid signature. Here,
additional clinical, morphological/IHC, and proteomics
features will increase confidence in the amyloid typing,
and these were applied to identify 24 examples of
ApoA-IV amyloid amongst over 2000 clinical samples
in our current proteomics database. The presence of dis-
tinct areas of ApoA-IV and TTR amyloid in patient 20 is
consistent with a diagnosis of two unrelated forms of
amyloidosis: ApoA-IV together with age-related wild-
type cardiac ATTR amyloidosis; this was also observed
in the original Swedish sample [17].
The most unexpected finding of our study was the
identification of signal sequence-containing peptides
p.15-43, p.17-43, p.18-43, p.19-43, and, most com-
monly, p.20-43 in ApoA-IV amyloid deposits. Some of
these peptides have previously been identified in a num-
ber of top-down proteomics analyses, for example in
cerebrospinal fluid [39] and breast cancer tissue [40],
although no biological role was ascribed. There was also
evidence for p.20-43 in the first proteomics identification
of renal ApoA-IV report from the Mayo Clinic, where
residue p.20A was highlighted as an identified tryptic
peptide, although its appearance did not receive any
comment [26]. At least one signal peptide was present
in 17/24 of the ApoA-IV amyloid cases, as well as in
the original Swedish cardiac sample. The identity of
the three main signal peptides, p.18-43, p.19-43, and
p.20-43, in patient-derived samples was confirmed by
chromatographic and mass spectrometric comparison
with authentic peptides and does not rely simply on a
Mascot-generated identification. ApoA-IV is a circulat-
ing protein that is synthesised in the intestine; therefore
it, and the associated signal-containing proteins present
in amyloid, should arise from the blood. Using targeted
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PRM analysis, we could identify all three signal peptides
present in blood of patient 3, although none were
detected in two other patients or in two healthy controls.
This would indicate that signal-containing proteins are
not a major component of circulating ApoA-IV. The sig-
nal does not appear to be associated with signature
ApoA-IV as only a single poor-quality signal peptide
was found in only one of the 266 non-ApoA-IV cases
with high scores (>800) examined. It was not possible
in the current study to determine whether the signal-
containing peptides identified in amyloid and in blood
are part of the full protein or a smaller truncated protein;
however, the limited coverage data would suggest that
the amyloidogenic ApoA-IV contains a lower propor-
tion of C-terminal protein than signature ApoA-IV.
The major circulating form of ApoA-IV (p.147N) is
inherently amyloidogenic [16], and so the presence of sig-
nal residues in ApoA-IV amyloid could simply be due to
an increased circulating concentration. This could be
caused by faulty processing, or secondary effects of the
additional signal sequence whereby altered lipid binding
could raise the free protein plasma concentration. Our
in vitro fibrillogenesis data with peptides p.18-43 to
p.21-43, showing that the addition of a single alanine res-
idue to the normal N-terminus causes increased fibrillo-
genicity, raise the possibility that the presence of signal
residues could exert a direct and deleterious effect on
the circulating protein. This could be propagated through
a number of mechanisms including direct destabilisation
of the protein, altered binding to lipids and other proteins
such as clusterin, or increased sensitivity to endogenous
protease activity or mechanical forces [36,41,42].
Although there is a large gap between the behaviour
of a small peptide in vitro and the stability of a protein
in the complex milieu of blood, our data are suggestive
of a potential causative relationship between the pres-
ence of signal sequence and enhanced ApoA-IV amyloi-
dogenicity. It may be that the presence of these signal
residues is no more than an additional marker that can
be applied to increase confidence in ApoA-IV amyloid
diagnosis; however, since ApoA-IV is involved in other
human diseases [43], the presence of signal sequence in
the circulating protein could have other deleterious path-
ophysiological effects.
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